US4680175A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Interferon administration vehicles
Assignee: AIM Immunotech Inc
•
Filing: 1984-02-07
•
Granted: 1987-07-14
•
Expires: 2004-02-07
Abstract
Abstract An interferon preparation to be administered topically is provided comprising: (a) a therapeutically effective amount of one or more interferons; (b) a vehicle base compatible with the interferon or interferons being administered; (c) an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or interferons due to proteolytic agents; and (d) an effective amount of one or more anti-microbial agents. In certain preferred embodiments of the invention, the vehicle base is prepared from a mixture of polyethylene glycols or includes hydroxyethyl cellulose as a thickening agent.
Inventors
- 👤 Leonard F. Estis
- 👤 Sean A. Evans
- 👤 Douglas Testa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 07:50
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/30; A61K47/36; A61K47/38; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P43/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
91 words
An interferon preparation to be administered topically to a patient suffering from a disease which responds therapeutically to interferon comprising: (a) one or more interferons, the amount of the one or more interferons being sufficient to therapeutically affect the disease from which the patient is suffering; (b) a vehicle base compatible with the interferon or interferons being administered; and (c) an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or interferons due to proteolytic agents.
Claim 2
Dependent Claim
91 words
An interferon preparation to be administered topically to a patient suffering from a disease which responds therapeutically to interferon comprising: (a) one or more interferons, the amount of the one or more interferons being sufficient to therapeutically affect the disease from which the patient is suffering; (b) a vehicle base compatible with the interferon or interferons being administered; and (c) an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or interferons due to proteolytic agents.
Claim 3
Dependent Claim
39 words
The interferon preparation of claim 1 wherein the protease inhibitors are selected from the group consisting of α 1 -antitrypsin inhibitor, α 2 -macroglobulin, soybean inhibitor, N.sup.α -tosyl-L-lysine chloromethyl ketone, phenylmethylsulfonyl fluoride, N.sup.α -tosylphenylalanine chloromethyl ketone and mixtures thereof.
Claim 4
Dependent Claim
16 words
The interferon preparation of claim 2 wherein the protease inhibitor is human α 1 -antitrypsin inhibitor.
Claim 5
Dependent Claim
32 words
The interferon preparation of claim 1 wherein the effective amount of one or more protease inhibitors produces a half-life for the interferon or interferons of at least fourteen days at 22° C.
Claim 6
Dependent Claim
32 words
The interferon preparation of claim 1 wherein the effective amount of one or more protease inhibitors produces a half-life for the interferon or interferons of at least one day at 37° C.
Claim 7
Dependent Claim
13 words
The interferon preparation of claim 1 wherein the vehicle base includes hydroxyethyl cellulose.
Claim 8
Dependent Claim
13 words
The interferon preparation of claim 1 wherein the vehicle base includes polyethylene glycol.
Claim 9
Dependent Claim
17 words
The interferon preparation of claim 1 further including an effective amount of one or more antimicrobial preservatives.
Claim 10
Dependent Claim
67 words
An α-interferon preparation to be administered topically to a patient suffering from a disease which responds therapeutically to α-interferon comprising: (a) one or more α-interferons, the amount of said one or more α-interferons being sufficient to therapeutically affect the disease from which the patient is suffering; and (b) a vehicle base compatible with the α-interferon or α-interferons being administered which includes hydroxyethyl cellulose as a thickening agent.
Claim 11
Dependent Claim
67 words
An α-interferon preparation to be administered topically to a patient suffering from a disease which responds therapeutically to α-interferon comprising: (a) one or more α-interferons, the amount of said one or more α-interferons being sufficient to therapeutically affect the disease from which the patient is suffering; and (b) a vehicle base compatible with the α-interferon or α-interferons being administered which includes hydroxyethyl cellulose as a thickening agent.
Claim 12
Dependent Claim
39 words
The α-interferon preparation of claim 9 further including an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or α-interferons due to proteolytic agents.
Claim 13
Dependent Claim
17 words
The α-interferon preparation of claim 9 further including an effective amount of one or more anti-microbial preservatives.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-13 | 1991-01-12 | 1991-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-13 | 1995-01-12 | 1995-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-13 | 1999-01-12 | 1999-07-14 | $7700.00 | Window Closed / Lapsed |